Pangaea Data Enters Collaboration with Sanofi to Improve Detection of AATD Through AI-Driven Clinical Decision Support

Press Release: Pangaea Expands its AI Platform to Support Decision-Making & Guideline-Concordance for MDT Tumor Boards Across Enterprise & Community Care

Microsoft & NVIDIA Documentary: Pangaea Data Closing Care Gaps

GO BACK

Early Detection of Cancer Cachexia Using Guideline-based AI

12:50 – 2:00 PM, October 7th, 2026, Edinburgh International Conference Centre, Scotland

Poster Presentation

Time & Date: 12:50 – 2:00 PM, October 7th, 2026

Session: Lunch & Poster Viewing Session

Learn how, in collaboration with NHS Lothian, Pangaea’s AI platform was configured on four cachexia guidelines (Fearon, Evans, GLIM and mGPS criteria) and demonstrated to outperform ICD coding, keyword-based NLP and baseline LLM prompting, achieving 96.4% precision for identifying patients with documented cancer cachexia, while achieving 100% sensitivity. Pangaea’s platformI also identified 104 potentially undiagnosed cases among 200 patients screened.

The results demonstrate how guideline-configured AI can move beyond conventional searches and generic LLM prompting to uncover clinically important signals hidden across structured and unstructured patient records, supporting earlier detection and intervention at the point of care.

Register to Meet Us

Attendees

Emily Comins
Biomedical Analyst,
Pangaea Data